Clinical Trial: Safety and Preliminary Efficacy of VIR-5525 and VIR-5525 + Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors

U.S., May 8 -- ClinicalTrials.gov registry received information related to the study (NCT06960395) titled 'Safety and Preliminary Efficacy of VIR-5525 and VIR-5525 + Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors' on April 21.

Brief Summary: This Phase 1, first-in-human (FIH), dose-escalation and dose-expansion study is designed to evaluate the safety, PK, and preliminary anti-tumor activity of VIR-5525 as a monotherapy and in combination with pembrolizumab in participants with solid tumors that are known to express EGFR.

The study will be conducted in the following 4 parts:

* Part 1: VIR-5525 monotherapy dose escalation

* Part 2: VIR-5525 monotherapy dose expansion

* Part 3: VIR-5525 plus pembrolizumab ...